Sigma-Aldrich Names New Sales & Research Biotech Leaders

Jul 05, 2007, 01:00 ET from Sigma-Aldrich Corporation

    ST. LOUIS, July 5 /PRNewswire-FirstCall/ -- Sigma-Aldrich Corporation
 (Nasdaq:   SIAL) is pleased to announce the promotion of two current senior
 executives to new responsibilities with the Company. Gerrit van den Dool,
 53, will assume expanded duties in the newly created position of Vice
 President Sales and Dr. David A. Smoller, 44, will become the new President
 of the Company's Research Biotech business unit.
     van den Dool, who will be responsible for sales for all three of the
 Company's research business units, joined Sigma-Aldrich in 1999 as the head
 of European Research Sales. He served in sales leadership roles at both
 Amersham-Pharmacia and Molecular Dynamics prior to joining the Company and
 holds degrees in Applied Physics from HTS Dordrecht University and in
 Business from Tilburg University of Eindhoven, both in the Netherlands. van
 den Dool will relocate to St. Louis from his current assignment in Munich,
 Germany, and will report directly to Jai Nagarkatti, President & CEO.
     Smoller joined Sigma-Aldrich as Vice President Research & Development
 in 2004 after founding and selling two successful biotech start-up
 companies - Genome Systems, Inc. and ProteoPlex, Inc. - over the prior
 decade. Since joining the Company, he had assumed broader responsibilities
 as Vice President R&D and Operations for Sigma-Aldrich's Research Biotech
 business unit and been named to the Company's Key Management Group in late
 2005. Smoller, who holds Ph.D. and B.S. degrees in Biology from Emory
 University and who completed his post doctoral fellowships with Washington
 University and Monsanto Company, will also report directly to Nagarkatti.
 Shaf Yousaf, the previous President of the Research Biotech business unit,
 has left the Company to pursue other interests.
     In a related move, Gilles Cottier, President of the Company's Research
 Essentials business unit and a member of its Executive Management Group,
 will add direct oversight of operations in India and China - two of the
 Company's most rapidly growing markets - to his existing duties.
     In commenting on these changes, President & CEO Jai Nagarkatti said:
 "We're excited by this opportunity to promote two of our most senior and
 seasoned executives to expanded roles in driving our Company's results. Two
 years after the successful launch of our 2005 Strategic Plan, Sigma-Aldrich
 is on track to achieve all of the Plan's targets. We remain financially
 strong; our Sigma-Aldrich and other brands remain number one in our
 markets; and our acquisitions and investments in exciting new technologies
 and process improvement efforts continue to bear fruit. By sharpening our
 focus even further, we'll expect even better things to come through
 Gerrit's, Dave's and Gilles' stewardship of our research sales, Biotech and
 emerging markets efforts, respectively."
     About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High
 Technology company. Our biochemical and organic chemical products and kits
 are used in scientific and genomic research, biotechnology, pharmaceutical
 development, the diagnosis of disease and as key components in
 pharmaceutical and other high technology manufacturing. We have customers
 in life science companies, university and government institutions,
 hospitals and in industry. Over one million scientists and technologists
 use our products. Sigma-Aldrich operates in 36 countries and has 7,600
 employees providing excellent service worldwide. We are committed to
 accelerating Customers' success through leadership in Life Science, High
 Technology and Service. For more information about Sigma-Aldrich, please
 visit our award-winning web site at

SOURCE Sigma-Aldrich Corporation